Login

Neuland Laboratories Ltd.

₹11558.8

Overview Charts Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Corp. Action Documents
Consolidated
Standalone

Neuland Laboratories Ltd.

₹11558.8

₹11558.8

-493.75 (-4.1%) - 4 Apr 2025 09:58 AM

About Company

Neuland Laboratories is a leading manufacturer of active pharmaceutical ingredients (APIs) and an end-to-end solution provider for the pharmaceutical industry’s chemistry needs. The company provides solutions across the full range of the pharmaceutical industry’s chemistry requirements, from the synthesis of library compounds to supplying NCEs and advanced intermediates at various stages in the clinical life-cycle, as well as commercial launch. Its core competency lies in the application of strong process chemistry to manufacturing in a regulatory compliant environment. Neuland has been at the forefront of facilitating and accelerating drug development and cGMP manufacturing of APIs.

Market Cap. ₹15,463 Cr.
52 Week - High/Low ₹18,100/5,540
P/E Ratio 51.66
P/B Ratio 12.11
Enterprise Value ₹15,469 Cr.
ROE % 26.48
RSI Value 52.93
EMA 50 12235.52
EMA 200 11855.57
Net Profit 300 Cr.
Net Profit 3year growth 273.12 Cr.
Net Profit 3 year (back) 80 Cr.
Debt to Equity 0.06 %
EPS Growth TTM -5.43 %
Current Ratio 2.12 %
100 Day SMA 13,634 Rs.
200 Day SMA 12,390 Rs.
21 Day SMA 11,504 Rs.
50 Day SMA 12,374 Rs.
Book Value 995 Rs.
EV/EBITDA Ratio 33
QoQ EPS Growth 217 %
QoQ Operating Profit Growth 132 %
QoQ Sales Growth 28 %
Sales Latest Quarter 398 Cr.
YoY Sales Growth 1 %
Market Cap. ₹15,463 Cr.
52 Week - High/Low ₹18,100/5,540
P/E Ratio 51.57
P/B Ratio 12.06
Enterprise Value ₹15,469 Cr.
ROE % 26.38
RSI Value 52.93
EMA 50 12235.52
EMA 200 11855.57
Net Profit 300 Cr.
Net Profit 3year growth -0.02 Cr.
Net Profit 3 year (back) 81 Cr.
Debt to Equity 0.06 %
EPS Growth TTM -5.43 %
Current Ratio 2.15 %
100 Day SMA 13,634 Rs.
200 Day SMA 12,390 Rs.
21 Day SMA 11,504 Rs.
50 Day SMA 12,374 Rs.
Book Value 1,000 Rs.
EV/EBITDA Ratio 33
QoQ EPS Growth 209 %
QoQ Operating Profit Growth 129 %
QoQ Sales Growth 28 %
Sales Latest Quarter 398 Cr.
YoY Sales Growth 1 %
Add Parameters

Growth

Valuation

Peer Comparison

Industry - Pharmaceuticals & Drugs

* Please refer to the Standalone data if Consolidated financial data for the company is not available.

Shareholding Pattern Numbers in percentages

Yearly

Insight market
Terms | Privacy | Contact Us
Copyright © 2025 All rights reserved with INVESMATE INSIGHTS PRIVATE LIMITED | All logos and Trademarks registered with their respective owners.